Q2 2023 BioArctic AB Earnings Call Transcript
Welcome to the BioArctic Q2 Presentation for 2023. (Operator Instructions)
Now, I will hand the conference over to the CEO, Gunilla Osswald; and CFO, Anders Martin-Löf. Please go ahead.
()-
Good morning, and welcome to BioArctic's presentation for the second quarter of 2023. I am Gunilla Osswald, and I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf.
I think it's very exciting times for BioArctic with LEQEMBI now granted full approval by the FDA last week and with CMS announcing a broader reimbursement. It's a beginning of a new era and BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. We can now help a large number of patients and their families, and I think that is extremely gratifying. And of course, I will talk more about LEQEMBI here today.
Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap since January this year, and this is our disclaimer.
Next
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
